final action
on 14 Aug 2024
Last Applicant/ Owned by
46701 Commerce Center Drive
Plymouth
MI
48170
Serial Number
97023072 filed on 12th Sep 2021
Registration Number
N/A
Correspondent Address
Roger H. Bora
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Scientific and technological services featuring testing, analysis and evaluation of human blood and other biological samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services featuring testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcar Read More
Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions, namely, testing, analysis and evaluation of blood and other biological samples for clinical treatment decision support purposes; Medical testing, analysis, and evaluation services in the nature of testing, analysis and evaluation of blood samples for diagnostic and treatment purposes; Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions in the nature of testing, analysis and evaluation of blood samples for the purpose of combining increased predictability of patient-specific drug efficacy, appropriate dose, drug-drug interactions, and likely adverse drug reactions with precise measurement of patient response to improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs
N/A
N/A
Scientific and technological services featuring testing, analysis and evaluation of human blood and other biological samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services featuring testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; Software as a service (SaaS) services featuring software for use in medical research data collection and management and database management, allowing physicians to share and receive clinical data, monitor patient data, monitor patient clinical data, monitor medications in a patient's circulation to support treatment decisions, develop clinical treatment decision support, develop other medical diagnostic products and prescription drugs for the purpose of improving patient outcomes in the field of healthcare, analyze and record testing, analysis and evaluation of human blood and other biological samples for the purposes of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving the initial drug prescribing practices, and identifying drug-drug interactions; Platform as a Service (PaaS) featuring computer software that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; Providing an interactive website featuring technology that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; scientific and technological services, namely, providing medical and scientific research featuring testing, analysis and evaluation of blood samples for the purpose of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving initial drug prescribing practices, identifying drug-drug interactions, developing clinical treatment decision support, and developing other medical diagnostic products and prescription drugs; scientific and technological services in the nature of testing, analysis and evaluation of blood and other biological samples for research purposes in the field of clinical trials; scientific and technological services, namely, research, analysis, and clinical testing in the fields of precision medicine for the purpose of combining pharmacogenomic drug treatment recommendations, identification and quantitative measurement of patient drug exposure with digital patient monitoring and digital therapy
N/A
N/A
No 97023072
No Service Mark
No 101396.002
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
11th Nov 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
11th Nov 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
14th Aug 2024 | NON-FINAL ACTION WRITTEN |
14th Aug 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
14th Aug 2024 | NON-FINAL ACTION E-MAILED |
29th Dec 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
18th Aug 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
01st Feb 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
01st Feb 2023 | LETTER OF SUSPENSION E-MAILED |
01st Feb 2023 | SUSPENSION LETTER WRITTEN |